Search bioRxiv⌕ Search

Biology subjects

Correia, J. S.

Publications and source records attributed to Correia, J. S..

2 recordsLinked to original sources

Understanding corticosterone fluctuations and HPA-axis regulation in a mouse model of Spinocerebellar ataxia type 3

Spinocerebellar ataxia type 3 (SCA3) or Machado-Joseph Disease (MJD) is a neurodegenerative disease caused by a CAG triplet expansion in the ATXN3 gene, primarily characterized by motor impairments. However, SCA3/MJD also includes mood-related comorbidities that affect both patients and their caregivers. Current treatments focus on symptom management and supportive care, as no disease-modifying therapies are available. Previously, we have demonstrated decreased glucocorticoid receptor (GR) expression in post-mortem SCA3 human and mouse brains and elevated peripheral corticosterone (CORT) levels in SCA3 mice at late disease stages. Impaired GR signaling is typically associated with hypothalamic-pituitary-adrenal (HPA) axis dysfunction, common in stress-related psychiatric diseases. Our study aimed to dissect the HPA-axis (dys)function and the effect of stress exposure on SCA3/MJD progression. Using the CMVMJD135 mouse model, we evaluated HPA-axis regulation in SCA3/MJD by measuring CORT levels throughout disease progression (6 to 34 weeks of age) under basal conditions and after acute stress. At week 35, these mice underwent a dexamethasone injection to challenge the HPA-axis, and the CORT levels were measured at different timepoints to evaluate the axis response. Additionally, we applied a 6-week chronic unpredictable stress (CUS) protocol in another cohort of mice starting at an early symptomatic stage to assess stress effects on the progression of motor impairments. Our findings indicate that serum CORT levels in SCA3 mice begin to rise between 26 to 30 weeks of age, with no impairment in the physiological response to acute stress. SCA3 mice were also able to normalize CORT levels after dexamethasone challenge, suggesting normal HPA-axis function. While CUS exposure had a transient negative impact on the motor phenotype, this effect did not persist throughout disease progression. In conclusion, stressful events, either acute or chronic, do not seem to be major determinants of disease severity in SCA3 mice.

neuroscience↗

Development of an optimized and scalable method for isolation of umbilical cord blood-derived small extracellular vesicles for future clinical use

Extracellular vesicles (EV) are a promising therapeutic tool in regenerative medicine. These particles were shown to accelerate wound healing, through delivery of regenerative mediators, such as microRNAs. Herein we describe an optimized and up-scalable process for the isolation of EV smaller than 200 nm (sEV), secreted by umbilical cord blood mononuclear cells (UCB-MNC) under ischemic conditions and propose quality control thresholds for the isolated vesicles, based on the thorough characterization of their protein, lipid and RNA content. Ultrafiltration and size exclusion chromatography (UF/SEC) optimized methodology proved superior to traditional ultracentrifugation (UC), regarding production time, standardization, scalability, and vesicle yield. Using UF/SEC, we were able to recover approximately 400 times more sEV per mL of media than with UC, and up-scaling this process further increases EV yield by about 3-fold. UF/SEC-isolated sEV display many of the sEV/exosomes classical markers and are enriched in molecules with anti-inflammatory and regenerative capacity, such as hemopexin and miR-150. Accordingly, treatment with sEV promotes angiogenesis and extracellular matrix remodeling, in vitro. In vivo, UCB-MNC-sEV significantly accelerate skin regeneration in a mouse model of delayed wound healing. The proposed isolation protocol constitutes a significant improvement compared to UC, the gold-standard in the field. Isolated sEV maintain their regenerative properties, whereas downstream contaminants are minimized. The use of UF/SEC allows for the standardization and up-scalability required for mass production of sEV to be used in a clinical setting.

bioengineering↗